Hypoglycemia and hyperglycemia: potential risks of polypragmasia in type 2 diabetes in hospital settings
https://doi.org/10.21518/2079-701X-2018-4-112-115
Abstract
Chronic hyperglycemia imposes damage on a number of cell types and is strongly correlated with the variety of related complications such as eyes, kidneys, cardiovascular system etc. This fact implies pharmacological treatment. Some are metabolic neutral, some are apt to provoke hypoglycemia and/or hyperglycemia, invert pharmacological response. To take into account a potential role of treatment on glucose level is crucial for pharmacotherapy in patient with T2DM. Besides, some drugs may distort the meaning of lab tests.
About the Authors
Yu. A. Sorokina
Nizhny Novgorod Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in Biology
Nizhny Novgorod
O. V. Zanozina
Nizhny Novgorod Medical University of the Ministry of Health of Russia;
N.A. Semashko Nizhny Novgorod Region Clinical Hospital
Russian Federation
Russian Federation
MD
Nizhny Novgorod
L. V. Lovtsova
Nizhny Novgorod Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in Medicine
Nizhny Novgorod
V. V. Stolyarova
Nizhny Novgorod Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD
Nizhny Novgorod
K. A. Borisova
Nizhny Novgorod Medical University of the Ministry of Health of Russia
Russian Federation
Nizhny Novgorod
Russian Federation
Nizhny Novgorod
I. A. Zhukov
Nizhny Novgorod Medical University of the Ministry of Health of Russia
Russian Federation
Nizhny Novgorod
Russian Federation
Nizhny Novgorod
References
1. Standards of specialized medical care in diabetes. Edited by Dedova II, Shestakova MV, Mayorov AYu. 8th Issue. Sakharny Diabet, 2017, 20(1S): 1-112. doi: 10.14341/DM20171S8.
2. Dedov II, Melnichenko GA, Andreeva EN, Arapova SD. Rational pharmacotherapy of endocrine system diseases and metabolic disorders: a guide for practitioners. Under the Society. Under the general editorship of Dedov II, Melnichenko GA. Moscow: Litterra, 2013. 1024 p.
3. Order of the Ministry of Health of the Russian Federation No 858н On the Approval of the Standard of Specialized Medical Care in Insulin-Dependent Diabetes Mellitus of November 9, 2012.
4. Shpakov AO, Derkach KV. Adenylyl cyclase signaling system in the liver and pancreas in the norm and in diabetic pathology. Rossiyskiy Fiziologicheskiy Zhurnal im. I.M. Sechenova, 2016, 102 (9): 1030-1050.
5. Sharoiko VV, Tennikova TB. Molecular mechanisms of insulin secretion by β-cells of islets of langergans and promising targets for the pharmacological treatment of diabetes mellitus. Nauka i Obrazovanie, 2015, 2 (78): 91-98.
6. Goodman and Gilman’s: the Pharmacological Basis of Therapeutics. Edited by Gilman AG, Hardman J. and Limberd L. M: Practice, 2006: 1286-1305.
7. Clinical pharmacology: national leadership. Ed. Yu.B. Belousova, V.G. Kukesa, V.K. Lepakhin, V.I. Petrova. Moscow: GEOTAR-Media, 2014. 976 p.
8. Guide on gerontology and geriatrics in 4 volumes. Volume 3. Ed. by Yarygin VN, Melentieva AS. Moscow: GEOTAR, 2010. 896 p.
9. Encyclopedia of medicines. 2017. RLS. Issue 25. Edited by Vyshkovsky GL. Moscow: RLS-2016. 1288 sec.
10. Koschel LV, Romantsova TI. The role of fenofibrate in the treatment of microvascular complications of type 2 diabetes mellitus. Sakharny Diabet, 2009, 4: 99-103
11. Strokov IA, Fokina AS. Alpha-lipoic acid as the main pharmacological treatment of diabetic polyneuropathy in the hospital and polyclinic. Meditsinsky Sovet, 2016, 17: 28-33.
12. Alexandrov AA, et al. Statins and diabetes: ignorance is not an argument. Lechashchiy Vrach, 2012, 7: 116-122.
13. /Drapkina OM, Kostyukevich MV. Statin use and the risk of developing diabetes. Sakharny Diabet, 2012, 2: 77-82.
14. Boursi B et al. The effect of past antibiotic exposure on diabetes risk. Eur J Endocrinol, 2015, 172(6): 639-648. doi: 10.1530/EJE-14-1163.
15. Hypoglycemia cases in the norfloxacin therapy (Ministry of Health and Social Development of the Russian Federation) Information letter of Center for Medicinal Products Evaluation and Research No. 76/Information-computing center to the Regional centers for monitoring the safety of medicines of 13.04.2011. http://www.labclinpharm.ru/ the date of circulation on 01/10/2018.
16. Clinical laboratory technologies. GOST R 53079.4-2008. Clinical laboratory research quality assurance. Part 4. Rules for conducting a pre-analytic stage. Moscow: Standartinform, 2009: 46-64.
Review
For citations:
Sorokina YA, Zanozina OV, Lovtsova LV, Stolyarova VV, Borisova KA, Zhukov IA. Hypoglycemia and hyperglycemia: potential risks of polypragmasia in type 2 diabetes in hospital settings. Meditsinskiy sovet = Medical Council. 2018;(4):112-115. (In Russ.) https://doi.org/10.21518/2079-701X-2018-4-112-115
Views:
812
Email this article 